Johnson & Johnson (NYSE:JNJ) updated its FY17 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $7.25 – $7.30 for the period, compared to the Thomson Reuters consensus estimate of $7.28.

A number of analysts recently issued reports on the company. Vetr raised Johnson & Johnson from a hold rating to a buy rating and set a $147.14 price objective on the stock in a report on Wednesday. Zacks Investment Research cut Johnson & Johnson from a buy rating to a hold rating in a report on Tuesday, December 12th. Citigroup assumed coverage on Johnson & Johnson in a report on Monday, September 25th. They set a neutral rating and a $140.00 price objective on the stock. BMO Capital Markets reissued a positive rating and set a $152.00 price objective (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Finally, Jefferies Group increased their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the stock a buy rating in a report on Monday, October 16th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of Hold and a consensus price target of $145.47.

Shares of Johnson & Johnson (NYSE JNJ) opened at $140.12 on Friday. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The firm has a market capitalization of $378,960.50, a PE ratio of 24.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the firm posted $1.68 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a $0.84 dividend. The ex-dividend date of this dividend was Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is currently 58.33%.

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares in the last quarter. FMR LLC raised its holdings in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares in the last quarter. Capital World Investors raised its holdings in shares of Johnson & Johnson by 4.1% during the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after buying an additional 1,050,000 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in shares of Johnson & Johnson by 4.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock valued at $2,363,788,000 after buying an additional 771,039 shares in the last quarter. 65.70% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Releases FY17 Earnings Guidance” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-releases-fy17-earnings-guidance/1779434.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.